首页 > 市场调查报告书 > 製药

生物製剂

重组蛋白市场规模、份额及成长分析（按产品、应用及地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1899232

重组蛋白市场规模、份额及成长分析（按产品、应用及地区划分）－2026-2033年产业预测

Recombinant Protein Market Size, Share, and Growth Analysis, By Product (Cytokines & Growth Factors, Antibodies), By Application (Drug Discovery & Development, Biopharmaceutical Production), By Region - Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 165 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，重组蛋白市场规模将达到 25.3 亿美元，到 2025 年将达到 27.1 亿美元，到 2033 年将达到 47.3 亿美元，在预测期（2026-2033 年）内，复合年增长率为 7.2%。

受医疗机构研发投入不断增加的推动，重组蛋白市场预计将迎来显着成长。重组蛋白的建构过程包括分离目标蛋白的转录区，并将其克隆到表达质体载体中，主要在微生物、酵母菌或培养的动物细胞中进行。重组蛋白在蛋白质-蛋白质交互作用研究中发挥关键作用，并在清洁剂、化妆品、营养保健品、诊断、疫苗和治疗等多个领域有广泛的应用。慢性病发病率的上升以及监管机构为遏制病毒感染而加强监管，是推动市场发展的主要因素。这些因素的综合作用预计将刺激对重组蛋白的需求激增，为市场带来巨大的发展机会。

重组蛋白市场驱动因素

受製药和生技公司研发投入增加的推动，重组蛋白市场正经历显着成长。资金的增加刺激了创新，并促进了新型治疗方法的开发。此外，监管环境的改善也为血友病和各种出血性疾病等罕见疾病带来了许多机会。研发活动的活性化，加上监管环境的变化，正在推动重组蛋白生产技术的进步，为患者拓展治疗选择，并推动市场发展。最终，这些因素共同创造了有利于科学进步和治疗创新的环境。

重组蛋白市场限制因素

重组蛋白市场面临一项重大挑战：众多主要企业在相对较小的市场中提供类似产品，导致激烈的价格竞争。这种市场饱和导致价格下行压力，因为各公司都在努力保持竞争力并吸引消费者。因此，价格下跌阻碍了市场成长潜力，使企业难以获得足够的利润率。在这种环境下，企业需要在产品策略中平衡品质和成本控制，从而限制了整个重组蛋白产业的发展。

重组蛋白市场趋势

重组蛋白市场正呈现出显着的发展趋势，这主要得益于抗体领域的快速成长。抗体在治疗、诊断和研究等多种应用领域中的应用日益广泛，而生物技术的进步正是推动这一快速成长的关键因素。高效的抗体筛选和设计技术，以及先进的表达系统，使得大规模生产成为可能，进一步促进了抗体的大规模生产。各公司正积极投资研发，以充分发挥重组抗体的潜力。与传统蛋白相比，重组抗体具有更高的特异性和更低的副作用。这种日益增长的需求预示着重组蛋白，尤其是在製药和生物製药领域，拥有广泛的发展前景。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲（MEA）
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争格局

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市集活动
主要企业市占率（2025 年）

主要企业简介

Bio-Techne（US）
Thermo Fisher Scientific Inc.（US）
Merck KGaA（Germany）
Danaher Corporation（US）
Abnova Corporation（Taiwan）
BioLegend Inc（US）
Bio-Rad Laboratories, Inc.（US）
BPS Bioscience, Inc.（US）
Enzo Biochem Inc.（US）
GenScript（China）
Miltenyi Biotec BV & Co. KG（Germany）
Proteintech Group, Inc.（US）
Sino Biological Inc.（China）
ACROBiosystems Group（US）
Aviva Systems Biology Corporation（US）
Sartorius CellGenix GmbH（Germany）
Icosagen（US）
Neuromics（US）
ProSpec-Tany TechnoGene Ltd.（Israel）
ProteoGenix SAS（France）

简介目录

Product Code: SQMIG35H2039

Recombinant Protein Market size was valued at USD 2.53 Billion in 2024 and is poised to grow from USD 2.71 Billion in 2025 to USD 4.73 Billion by 2033, growing at a CAGR of 7.2% during the forecast period (2026-2033).

The recombinant protein market is set for significant growth driven by increased investment from healthcare organizations in research and development. The process involves isolating coding sequences of target proteins and cloning them into expression plasmid vectors, primarily utilizing microbes, yeast, or cultured animal cells. Recombinant proteins play a crucial role in studying protein-protein interactions and have diverse applications across various sectors, including detergents, cosmetics, food supplements, diagnostics, vaccinations, and therapies. The rising incidence of chronic diseases and the expansion of regulatory bodies aiming to mitigate viral infections are key contributors to the market's advancement. As these factors align, the demand for recombinant proteins is expected to soar, positioning the market for substantial opportunities.

Top-down and bottom-up approaches were used to estimate and validate the size of the Recombinant Protein market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Recombinant Protein Market Segments Analysis

Global Recombinant Proteins Market is segmented by Product, Application, Host cell, End User and region. Based on Product, the market is segmented into Cytokines & Growth Factors (Interferons (IFNs), Interleukins (ILs), Others), Antibodies, Immune Checkpoint Proteins, Virus Antigens, Enzymes (Kinases, Metabolic Enzymes, Others), Recombinant Regulatory Proteins, Hormones, Others. Based on Application, the market is segmented into Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Biopharmaceutical Production, Research (Academic Research, Biotechnology Research), Diagnostics, and Others. Based on Host cell, the market is segmented into Mammalian Systems, Insect Cells, Yeast & Fungi, Bacterial Cells, and Others. Based on End User, the market is segmented into Pharmaceutical & Biopharmaceutical, Academic Research Institutes, Contract Research Organizations, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Recombinant Protein Market

The Recombinant Protein market is experiencing significant growth driven by the rising investments in research and development from pharmaceutical and biotechnology companies. Enhanced funding has facilitated innovation, enabling the development of novel therapies. Additionally, an increase in regulatory requirements has opened up numerous opportunities for targeting rare diseases, such as hemophilia and various bleeding disorders. This combination of heightened R&D activity and the regulatory landscape is paving the way for advancements in recombinant protein production, thereby expanding treatment options for patients and propelling the market forward. As a result, the landscape is becoming increasingly conducive to scientific progress and therapeutic innovation.

Restraints in the Recombinant Protein Market

The recombinant protein market faces significant challenges due to intense price competition arising from numerous key players entering a relatively confined market with similar product offerings. This saturation leads to a downward pressure on pricing, as companies strive to attract consumers while maintaining competitiveness. Consequently, as prices decrease, the potential for market growth may be hindered, making it difficult for companies to achieve substantial profit margins. This environment creates constraints on the overall development of the recombinant protein sector, as businesses navigate the balance between maintaining quality and lowering costs in their product strategies.

Market Trends of the Recombinant Protein Market

The recombinant protein market is witnessing a significant trend driven by the rapid growth of the antibody segment, which is increasingly being adopted across diverse applications such as therapeutics, diagnostics, and research. This surge is propelled by advancements in biotechnology that facilitate the efficient selection and engineering of antibodies, enabling their large-scale production through sophisticated expression systems. Companies are actively investing in research and development to harness the potential of recombinant antibodies, which offer enhanced specificity and reduced side effects compared to traditional proteins. This burgeoning interest indicates a robust future for recombinant proteins, particularly in the pharmaceutical and biopharmaceutical sectors.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Pricing Analysis
Technology Analysis
Value Chain Analysis
Patent Analysis
Customer & Buying Criteria Analysis
Regulatory Analysis
PESTEL Analysis

Recombinant Proteins Market, By Product

Market Overview
Cytokines & Growth Factors
- Interferons (IFNs)
- Interleukins (ILs)
- Others
Antibodies
Immune Checkpoint Proteins
Virus Antigens
Enzymes
- Kinases
- Metabolic Enzymes
- Others
Recombinant Regulatory Proteins
Hormones
Others

Recombinant Proteins Market, By Application

Market Overview
Drug Discovery & Development
- Biologics
- Vaccines
- Cell & Gene Therapy
Research
- Academic Research
- Biotechnology Research
Biopharmaceutical Production
Diagnostics
Other Applications

Recombinant Proteins Market, By Host Cell

Market Overview
Mammalian Systems
Insect Cells
Yeast & Fungi
Bacterial Cells
Other Host Cells

Recombinant Proteins Market, By End User

Market Overview
Pharmaceutical & Biopharmaceutical Companies
Biotechnology Companies
Academic & Research Institutes
Contract Research Organizations
Other End Users

Recombinant Proteins Market Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Bio-Techne (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abnova Corporation (Taiwan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioLegend Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BPS Bioscience, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Enzo Biochem Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GenScript (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Miltenyi Biotec B.V. & Co. KG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Proteintech Group, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sino Biological Inc. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ACROBiosystems Group (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aviva Systems Biology Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sartorius CellGenix GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Icosagen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neuromics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ProSpec-Tany TechnoGene Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ProteoGenix S.A.S (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments